Introduction
New cardiovascular (CV) risk markers like highsensitivity C-reactive protein (hsCRP), 1, 2 brain natriuretic peptide (BNP), 3 N-terminal (Nt) proBNP 4 and urine albumin/creatinine ratio (UACR) 5 have been demonstrated to predict CV events in the general population. Although they add significantly to traditional CV risk factors their role in risk stratification and identification of subjects for primary prevention is not yet clear. 6 We have previously shown that hsCRP, Nt-proBNP and UACR provide additive prognostic information in the general population 6 as well as in hypertensive patients 7 probably because they are markers of damage in different parts of the CV system occurring at different time points in the atherosclerotic process. 6 High hsCRP is thought to reflect the early atherosclerotic process, 8 high Nt-proBNP is thought to reflect the haemodynamic load on the heart and thereby CV hypertrophy and left ventricular dysfunction, 9 and high UACR is thought to reflect endothelial dysfunction and microvascular damage. 10 Therefore, it is likely that the predictive values of these three risk markers will differentiate depending on presence or absence of subclinical and overt CV disease. It is generally accepted that primary prevention is indicated in subjects with an estimated 10-year risk of CV death of 5% or above as estimated by HeartScore. 11, 12 However, it is less clear whether primary prevention is appropriate in subjects with a HeartScore below 5%, but with high CV risk indicated by new risk markers.
Therefore, the aim of this study was (1) to investigate the predictive values of hsCRP, NtproBNP and UACR on the composite CV end point (CEP) of CV death, non-fatal myocardial infarction and non-fatal stroke in different CV risk groups based on HeartScore and history of CV disease or diabetes, and (2) to determine whether hsCRP, Nt-proBNP and UACR added to risk prediction based on HeartScore and history of diabetes or CV disease by actually changing the original risk classification.
Methods

Study design
In 1982-84, a random population sample of 4807 individuals aged 31, 41, 51 or 61 living near Glostrup University Hospital, were invited to participate in a population survey in which 82.6% participated. In 1993-94, 3785 former participants still living in the area were re-invited and 2656 (70.2%) accepted to participate in following investigations. During a single study visit in 1993 all traditional cardiovascular risk factors were measured, blood samples obtained for plasma glucose, serum insulin and lipid profile, 13 serum Nt-proBNP and serum hsCRP, and a morning urine sample was collected to calculate UACR. The participants completed a questionnaire concerning their past and current medical history, intake of medication and lifestyle. 6 The study was approved by the local ethical committee and the subjects gave informed consent. After 9.5 years, a complete follow-up regarding death was obtained through information from the Civil Registration System until October 2003. Information on cardiovascular mortality was obtained from blinded classification of death certificates and information on hospitalization was recorded from The Danish National Health Register, the data from which have previously been validated.
14 During the follow-up, CEP occurred in 204 subjects (9.4 per 1000 person-years of follow-up) and CV death in 128 subjects (5.8 per 1000 personyears of follow-up).
In the actual study, we included the 2460 subjects in whom we had available data. The current study population did not differ from the subjects with missing data and were before the analyses divided in following three CV risk groups: A patient group of 472 subjects who received CV medication or had known diabetes, prior myocardial infarction or stroke. In the remaining 1988 apparently healthy subjects the expected 10-year risk of CV death were calculated using HeartScore. The 559 subjects with an expected 10-year risk of CV death above 5% were classified as having high risk whereas the remaining 1429 subjects with an expected 10-year risk of CV death below 5% were classified as having lowmoderate risk.
We found it ethically unacceptable to consider withholding prophylactic intervention in subjects with high risk based on HeartScore. Therefore, we decided beforehand that a HeartScore high-risk subject with low new risk markers could not be reclassified to a low-moderate risk subject. We also decided to ignore re-classification of high risk to very high risk because it would not have any clinical consequences. As HeartScore has been criticized for underestimating CV risk in younger subjects, we planned to recalculate CV risk regarding subjects aged 41 or 51 years as being 60 years. We have not separated subjects according to different CV medication because only 61 subjects received lipid-or glucose-reducing medication and only 328 subjects received a blood pressure reducing agent of any kind.
Blood pressure
Office BP and heart rate were measured sitting after 5 min of rest with the participants arm at heart level with a random zero mercury sphygmomanometer and the mean of two measurements was reported. Heart rate was counted over 15 s.
Assays
Serum hsCRP concentration was determined using a particle-enhanced immunoturbidimetry assay (Roche/Hitachi) range 0.1-20 mg l
À1
and lowest detection limit 0.03 mg l À1 . Serum Nt-proBNP concentration was determined using Elecsys proBNP sandwich immunoassay on an Elecsys 2010 (Roche Diagnostics, Mannheim, Germany). The analytical range was 5.1-34 927 pg ml À1 . Between-assay coefficients of variation in low and high ranges of Nt-proBNP are reported to be 4.8 and 2.7%. 15 Serum was frozen immediately at À20 1C to be examined in July 2003. We have earlier published data showing that HsCRP 16 as well as Nt-proBNP 17 appear to be stable in the frozen samples.
Urine albumin concentration was determined by standard methods 18 using a turbidimetric method (Hitachi 717 analyzer, Roche Diagnostics) on a single urine specimen taken in the morning. Urine creatinine was analyzed using the Jaffé reaction without deproteinizing and then quantified by a photometric method (Hitachi 717 analyzer, Roche Diagnostics Mannheim). Urine albumin/creatinine ratio was calculated.
Statistics
Statistical analyses were performed using SPSS 12.0 (SPSS, Chicago, IL, USA) software. Pearson's w 2 test was used to determine differences in categorical variables between groups. Based on the distribution of residuals from the models and test for linearity and proportional hazard assumption in Cox-regression analyses, all three novel risk markers required logarithmic transformation. For log(hsCRP), log (Nt-proBNP) and logUACR, hazard ratios (HRs) and their 95% confidence intervals (in brackets) were assessed in the whole group to test for modulation by CV risk group based on HeartScore using formal interaction tests. HRs for log(hsCRP), log(Nt-proBNP) and logUACR were also calculated in each group using univariate Cox-regression analyses. In subjects with known diabetes or CV disease we used multiple Cox-regression analyses to adjust for age, gender and smoking habits, but not alcohol consumption, physical activity, education and occupation as their contribution was insignificant. 6 Finally, we used SAS software, version 9.1 (SAS Institute, Cary, NC, USA) to calculate the 10-year absolute risk of CV death or CEP at different levels of hsCRP, Nt-proBNP and UACR in risk groups based on HeartScore. Based on pre-specified gender adjusted cutoff values with a specificity of 90% in apparently healthy subjects, 19 negative and positive predictive values were calculated for the three novel risk markers in each of the three risk groups. Whether the three new risk markers added to HeartScore was tested by the likelihood ratio-test and quantified by receiver-operating characteristic (ROC) plots. Table 1 Subjects with high as compared with lowmoderate CV risk according to HeartScore, had also as expected higher incidence of CEP (15.9 (75 events) vs 3.1 (41 events) per 1000 person-years of follow-up) and CV death (9.5 (46 events) vs 1.1 (15 events) per 1000 person-years of follow-up, both Po0.001). The incidence of CEP and CV death were further increased in subjects with known CV disease or diabetes (22.1 (88 events) and 17.3 (67 events) per 1000 person-years of follow-up). As 82% of the subjects with low-moderate CV risk were either 41 or 51 years, one-third of the subjects with lowmoderate risk would have high CV risk according to HeartScore if they were regarded as being 60 years. Although this subgroup had higher incidence of CEP (5.0 (21 events) vs 2.2 (20 events) per 1000 personyears of follow-up, Po0.01) and insignificant higher incidence of CV death (1.4 (6 events) vs 1.0 (9 events) per 1000 person-years of follow-up, NS) compared with the remaining two-thirds of the lowmoderate risk group, the actual 10-year risk of CV death did not exceed 5%.
Results
Baseline characteristics
Prognostic value of UACR, hsCRP and Nt-proBNP
In univariate Cox-regression analyses in healthy subjects with low-moderate or high CV risk based on HeartScore high log(hsCRP) predicted CEP in both groups, but CV death only in subjects with high CV risk (P ¼ 0.18 for interaction) (Figure 1a ). High log(Nt-proBNP) only predicted CEP and CV death in subjects with high CV risk (Po0.05 for interaction) (Figure 1b) . LogUACR predicted CEP and CV death independently of CV risk based on HeartScore (Figure 1c) . However, if subjects aged 41 or 51 years were regarded as being 60 years when estimating CV risk, log(hsCRP) did not predict neither CEP (HR ¼ 1.2(0.5-2.9)) nor CV death (HR ¼ 0.6(0.1-2.5)) in subjects with low-moderate CV risk whereas logUACR still did (HR CEP ¼ 2.9(1.5-5.5) and HR CV death ¼ 3.2(1.3-7.8)). In subjects with lowmoderate CV risk, the actual 10-year risk of CV death (Figure 1a) or UACR 41.6 mg mmol À1 (Figure 1c ). In univariate as well as multivariate Cox-regression analyses in subjects with known diabetes or CV disease, high log(Nt-proBNP) and logUACR predicted CEP and CV death, whereas log(hsCRP) only predicted CEP significantly in univariate Coxregression analysis (Table 2) .
Predictive value of UACR, hsCRP and Nt-proBNP Using pre-specified gender adjusted cutoff values in the same three risk groups, UACR performed the best in subjects with low-moderate as well as high CV risk (Table 3) even if subjects aged 41 or 51 years were regarded as being 60 years when calculating CV risk (data not shown). UACR was high in 8.4% (120/1429) of subjects with low-moderate risk and 18.2% (102/559) of subjects with high risk predicting 10 and 25 CEPs, respectively. In subjects with known CV disease or diabetes, UACR and Nt-proBNP performed equally well (Table 3) . UACR was high in 33% (143/434) of subjects with known CV disease or diabetes predicting 54 CEPs of which 43 were fatal, whereas Nt-proBNP was high in 34% (148/434) predicting 55 CEPs of which 45 were fatal. HsCRP performed the worst in subjects with high CV risk or known CV disease or diabetes and intermediate in subjects with low-moderate risk (Table 4) . HsCRP was high in 8.7% (124/1429) of subjects with low-moderate risk predicting six CEPs. However, if subjects aged 41 or 51 years were regarded as being 60 years when estimating CV risk, high hsCRP was not associated with higher incidence of CEP (2.2 vs 2.7 per 1000 person-years of follow-up, NS) in subjects with low-moderate risk.
Incidence of CV events (%)
Incidence of CV events (%) Figure 1 The calculated 10-year absolute risk of the composite cardiovascular (CV) end point (CEP) (full lines) and CV death (dotted lines) in subjects with an estimated (HeartScore) 10-year risk of CV death below (grey lines) or above (black lines) 5% at different levels of high-sensitivity C-reactive protein (hsCRP) (a), N-terminal pro-brain natriuretic peptide (Nt-proBNP) (b) and urine albumin/creatinine ratio (UACR) (c). Hazard ratios (HR) and their 95% confidence intervals are calculated using Cox-regression analyses. **Po0.01 and ***Po0.001.
New risk markers and risk re-classification MH Olsen et al
Using all three new CV risk markers together, the sensitivities and the negative predictive values were increased significantly, whereas the specificities and positive predictive values were reduced even more (data not shown). However, using UACR and hsCRP in subjects with low-moderate risk and (Table 4 ). This combination of the three new risk markers added significantly to the CV risk prediction (Po0.001) and the area under receiver-operating characteristic plots increased from 0.72 (0.99-0.81) to 0.77 (0.74-0.81) for CEP and 0.77 (0.73-0.81) to 0.82 (0.79-0.86) for CV death. Either UACR or hsCRP was high in 16% (228/1429) of subjects with lowmoderate CV risk predicting 14 CEPs, one-third of all CEPs in that group. In other words 34% (14/41) of low-moderate risk subjects experiencing a CEP were rightfully re-classified as having high risk, but at the same time 15% (214/1429) of low-moderate risk subjects not experiencing a CEP were wrongfully re-classified as having high risk. In subjects with known CV disease or diabetes, combined absence of high UACR and high Nt-proBNP was found in 52% (244/472) of the subjects and only 13 of these subjects experienced a CEP, 15% of all CEPs in that group. In other words 15% (13/85) of subjects with known CV disease or diabetes experiencing a CEP were wrongfully reclassified as having moderate-high risk, whereas 49% (231/472) of subjects with known CV disease or diabetes not experiencing a CEP were rightfully re-classified as having moderate-high risk. In summary the risk classification by HeartScore was changed significantly in 472 subjects (19%) when using the three new risk markers and their pre-specified gender adjusted cutoff values in addition to HeartScore. As the actual 10-year risk of CV death exceeded 5% in subjects with low-moderate risk for UACR41.6 mg mmol À1 , we tested the performance of UACR using the pre-specified gender adjusted cutoff value (1.35/1.59 mg mmol À1 ) defined to give a specificity of 95% in a group of healthy subjects aged 41-71 years. As expected the specificity and positive predictive value increased whereas the sensitivity decreased (Table 4) . UACR was only especially high in 4.3% (61/1429) of the subjects with low-moderate risk predicting seven CEPs of which three were fatal. The positive predictive value for CV death was 4.9%, which was close to the 5% indicating primary prevention.
Discussion
This study provides two new observations: Firstly, in subjects with estimated low-moderate CV risk using HeartScore, high UACR or high hsCRP predicted CEP and identified a subpopulation with high CV risk. Secondly, in subjects with known CV disease or diabetes, low UACR and low Nt-proBNP predicted absence of CEP and identified a subpopulation with moderate-high risk.
Prognostic performance of hsCRP
In subjects with low-moderate CV risk based on HeartScore, hsCRP predicted CEP as well as CV death probably because hsCRP is a marker of early atherosclerotic changes. This is supported by earlier studies by Ridker et al.
1 in postmenopausal women. Despite the fact that hsCRP above 6.0/7.3 mg l À1 in subjects with low-moderate CV risk only identified six CEPs, hsCRP 45.6 mg l À1 was associated with a 10-year risk of CV death higher than 5% supporting primary prevention. 12 On the other hand, our data suggested that high hsCRP did not add new prognostic information in subjects with low-moderate CV risk, if subjects aged 41 or 51 years were regarded as being 60 years when calculating CV risk 12 suggesting that the elevated hsCRP just reflected slightly elevated traditional CV risk factors in younger subjects. However, making subjects aged 41 or 51 years older almost doubled the number of subjects eligible for primary prevention due to high CV risk based on HeartScore, which is not rational.
Prognostic performance of Nt-proBNP High Nt-proBNP predicted CEP as well as CV death in subjects with high CV risk based on HeartScore or in subjects with known CV disease or diabetes, probably because Nt-proBNP is a marker of subclinical CV hypertrophy and left ventricular dysfunction developing later in the atherosclerotic process. This is supported by several studies in patients with heart failure 20 and acute coronary syndrome 21 as well as by the fact that earlier studies in the general population have demonstrated significant prognostic value of Nt-proBNP in elderly subjects with high probability of subclinical CV disease. 3 In subjects with known CV disease or diabetes, Nt-proBNP above 110/164 pg ml À1 was found in one-third of the subjects and predicted CEP with a very high positive predictive value of 37.2% representing almost a fivefold higher event-rate compared with the rest of the subjects with known CV disease or diabetes. Therefore, Nt-proBNP was an extremely powerful risk marker in subjects with known CV disease or diabetes.
Prognostic performance of UACR High UACR predicted CEP as well as CV death in all subjects supporting the hypothesis that UACR is a marker of endothelial dysfunction 22 known to precede atherosclerosis 23 as well as a marker of later subclinical microvascular damage. 24 In subjects with low-moderate CV risk based on HeartScore and therefore traditionally not eligible for primary prevention, the actual 10-year risk of CV death exceeded 5% for UACR 41.6 mg mmol À1 underlining the importance of primary prevention with healthy diet, physical exercise, smoking cessation, blood pressure and cholesterol monitoring/lowering according to general guidelines in this small subgroup of 61 subjects (4.3%). However, UACR above 0.73/1.06 mg mmol À1 was found in 120 subjects with low-moderate CV risk and identified as much as 10 CEPs with a very high negative predictive value of 98%. Taking into account that these subjects were rather young, this suggests that primary prevention should be emphasized already at levels of UACR around one mg mmol À1 , which is also close to the value we have suggested as abnormal in patients with hypertension. 25 
Clinical implications
Our data suggested that hsCRP should be used in subjects with low-moderate CV risk based on HeartScore, Nt-proBNP in subjects with high CV risk, known CV disease or diabetes and UACR in all subjects. This is consistent with our earlier findings that hsCRP had prognostic importance especially in 41 or 51 year-old men, Nt-proBNP especially in 61 or 71 year-old subjects and UACR independently of age. 19 Combined use of UACR and hsCRP in subjects with low-moderate CV risk identified a rather large subpopulation of 228 subjects (16%) with high CV risk (14 CEPs) in which primary prevention including lifestyle changes as well as blood pressure and cholesterol monitoring/lowering according to general guidelines should be emphasized by doctors despite low-moderate CV risk based on HeartScore. Measuring UACR and hsCRP in subjects with lowmoderate CV risk seems to be a clinically relevant supplement to HeartScore as 34% is re-classified rightfully vs 15% wrongfully. However, in a daily clinic, we do not suggest that these two new risk markers are measured routinely in subjects with low-moderate CV risk, but it is measured on an individual basis either in subjects with moderate CV risk or in subjects especially afraid of developing CV disease.
Combined use of UACR and Nt-proBNP in subjects with known CV disease or diabetes identified a large subpopulation of 52% (244 subjects) with only moderate-high risk (13 CEPs) who could be treated in primary care and an almost equally large group of subjects with extremely high CV risk (75 CEPs) who should be referred for specialist care to optimize treatment. Measuring UACR and Nt-proBNP seems to be relevant in patients with known CV disease or diabetes, as 49% is reclassified rightfully vs 15% wrongfully.
Summary
In subjects with low-moderate estimated CV risk based on HeartScore, high UACR or high hsCRP predicted CEP as well as CV death, and identified an apparently healthy subpopulation of 16% with high CV risk. In subjects with known CV disease or diabetes, low UACR and low Nt-proBNP predicted absence of CEP as well as CV death and identified a subgroup of 52% with only moderate-high CV risk.
In other words, the CV risk based on HeartScore was significantly re-classified in 19% of the population when the three new risk markers were used in addition to HeartScore.
Limitations
As the data on prior CV disease was self-reported, we chose a conservative, but probably an accurate definition using only previous myocardial infarction or stroke as prior CV disease. The fact that 30% of the subjects originally examined in 1982-84 did not participate in 1993-94, may have reduced the overall CV risk of the population examined in 1993-94, but because of a complete follow-up in 2003 this may not affect the prognostic effect of the new risk markers. Although, we did not have data on serum creatinine, no subject had severe renal failure and excluding subjects with UACR above 3.5 mg mmol À1 did not change the results significantly (data not shown).
As approximately 5% of subjects had hsCRP410 mg l À1 and 1% had hsCRP425 mg l
À1
and we did not test for infection, some of the hsCRP elevation may be because of infection. However, excluding the upper 1 and 5% did not change the results significantly (data not shown) and Ridker et al. have previously demonstrated that even very high levels of hsCRP is clinically useful.
26
In the group of subjects with known CV disease or diabetes, different types of medication may have influenced the level of the three new risk markers although only UACR was elevated in the 61 subjects receiving lipid-or glucose-reducing medication as well as in the 328 subjects receiving blood pressure reducing agents.
